Fresenius Medical Care

Fresenius Medical Care AG & Co. KgaA provides products and services for individuals with renal diseases. The firm develops and manufactures health care products, which includes dialysis and non-dialysis products. It operates through the following segments: North America Segment, EMEA Segment, Asia-Pacific Segment and Latin America Segment. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Fresenius Medical Care AG engages in the provision of products and services for individuals with renal diseases. It operates through the Care Enablement and Care Delivery segments. The Care Enablement segment is involved in the healthcare products business including research and development, manufacturing, supply chain, and commercial operations as well as supporting functions, such as regulatory and quality management. The Care Delivery segment focuses on the health care services for the treatment of CKD, ESRD, and other extracorporeal therapies, including value and risk-based care programs. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.

Divestments in 2023 are important milestones of the Company's execution against its Portfolio Optimization which are part of the set strategic aspirations Delivers on commitment to improve leverage ratio by allocating expected EUR 0.5 billion proceeds from divestments to deleverage BAD HOMBURG, Germany , Jan. 8, 2024 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, today announced updates from transactions in 2023 as part of the Company's ongoing Portfolio Optimization Program. Refocused on businesses and markets with the best strategic fit and greatest scale and sustainable profitable growth potential, Fresenius Medical Care continues exiting unsustainable markets, divesting noncore and dilutive assets and prioritizing deleveraging as part of a disciplined and stringent approach to capital allocation.

Fresenius Medical Care Executes on Its Strategic Portfolio Optimization Program and Announces Key Transactions

Fresenius Medical Care has seen a recovery in its share price after a dip in October 2023, presenting an attractive upside potential. The company's 3Q23 results showed continued organic growth, successful execution of its turnaround plan, and raised earnings outlook. While FMS still has average margins and profitability compared to its peers, it remains undervalued and offers a compelling investment opportunity.

Fresenius Medical Care: What Can We Expect For 2024E

Fresenius has hired UBS to manage the sale of its rehabilitation care clinic business as the German healthcare group focuses on core activities, Frankfurter Allgemeine Zeitung reported on Friday, citing financial sources.

Fresenius plans to sell rehabilitation care clinics - FAZ

Dialysis group Fresenius Medical Care said on Wednesday that data including medical records on 500,000 patients and former patients were stolen from a U.S. subsidiary's database.

Fresenius Medical Care says data on 500,000 people stolen in U.S.

Change of legal form simplifies the corporate governance structure as a German stock corporation (Aktiengesellschaft) The composition of the Management Board remains as before; the new Supervisory Board assumes office with immediate effect Business model and strategic plan remain strong and continue to translate into improved operating performance BAD HOMBURG, Germany , Nov. 30, 2023 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, announces the successful completion of its change of legal form from a partnership limited by shares (Kommanditgesellschaft auf Aktien, KGaA) into a German stock corporation (Aktiengesellschaft, AG) as of November 30, 2023. With this important milestone, Fresenius Medical Care is opening a new chapter in the history of the Company with a simplified corporate governance structure that gives the Company more flexibility and autonomy.

Fresenius Medical Care completes change of legal form into a German stock corporation

Fresenius Medical (FMS) wins legal dispute against the U.S. government. Both revenues and operating income will benefit from the settlement agreement.

Fresenius Medical (FMS) Ups '23 Outlook After Legal Settlement

WALTHAM, Mass. , Nov. 21, 2023 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, resolved a legal dispute with the U.S. government, for accounts receivable in legal dispute, and entered into a final and legally binding settlement agreement today, whereby the company will receive a payment from the U.S. government.

Fresenius Medical Care enters into favorable settlement agreement with U. S. government with positive earnings impact of approx.

Abbott Labs

AstraZeneca

Anheuser-Busch InBev

Crown Hlds

Chipotle

DoorDash

Darden Restaurants

Hershey

Keurig Dr Pepper Inc

Eli Lilly

Mondelez

Novo Nordisk

PepsiCo

Teleflex

That's the message from many corporate executives who have lately been peppered with questions about how Wegovy, Ozempic and other drugs widely used for weight loss may impact their bottom line.

Who's afraid of Ozempic? From restaurants to package makers, companies work to calm investors' GLP-1 jitters.

Fresenius Medical's (FMS) third-quarter revenues suffer due to unfavorable currency movement. However, the company's transformational plans continue to benefit its operating income.

Fresenius Medical (FMS) Q3 Earnings Miss, Operating Margin Up

Fresenius Medical Care AG & Co. KGaA (FMS) Q3 2023 Earnings Call Transcript

Continued solid organic growth in Care Enablement and Care Delivery including sequentially stable same market treatment growth in the U.S. Successful execution on turnaround plan driving productivity improvements in Care Delivery and pricing in Care Enablement FME25 transformation savings fully on track Continued execution on portfolio optimization strategy FY 2023 earnings outlook raised WALTHAM, Mass. , Nov. 1, 2023 /PRNewswire/ -- Helen Giza, Chief Executive Officer of Fresenius Medical Care, said: "Our unwavering focus on executing against our strategic plan and the successful implementation of turnaround measures to date, continue to translate into improved operating performance.

Fresenius Medical Care continues to execute on turnaround plan and raises 2023 earnings outlook due to strong operational performance in first nine months and solid business outlook for the fourth quarter

WALTHAM, Mass. , Oct. 31, 2023 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, has appointed Craig Cordola (52) as new Management Board member for the globally operating Care Delivery segment.

Fresenius Medical Care appoints Craig Cordola as new Management Board member for Care Delivery

Company-wide research offers novel pathways for enhancing kidney patient care using data-driven insights and real-world evidence WALTHAM, Mass. , Oct. 31, 2023 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, today announced the presentation of over 60 company-affiliated research abstracts at the American Society of Nephrology's (ASN) Kidney Week 2023 taking place November 2-5 in Philadelphia.

Fresenius Medical Care Demonstrates Commitment to Innovating Dialysis and Kidney Disease Care with Presentations at the American Society of Nephrology (ASN) Kidney Week 2023

Powerful Cloud-Based Data Asset to Drive Improvements in Care Quality and Patient Outcomes as the Largest Multinational, Longitudinal Database of its kind Achievement Part of Company's Long-Term AI Strategy and Ongoing Digital Transformation Efforts WALTHAM, Mass. , Oct. 26, 2023 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, today announced the phase-one completion of the company's first anonymized global dialysis dataset—coined the Apollo database project—the foundation of the company's long-term AI aspirations.

Fresenius Medical Care Achieves Key AI Milestone With First-Phase Completion of Largest Global Dialysis Clinical Dataset

ImmunoGen

Vericel

Several Zacks Medical sector stocks were recently added to the Zacks Rank #1 (Strong Buy) list over the last week and should be viable options for investors during economic uncertainty as healthcare is always essential.

Top Medical Stocks to Buy Amid Recent Market Volatility

WINCHESTER, Va. , Oct. 18, 2023 /PRNewswire/ -- Capital Square, one of the nation's leading sponsors of tax-advantaged real estate investments and an active developer and manager of multifamily communities, announced today the sale of a medical building in Winchester, Virginia.

Capital Square Delivers 149.59% Total Return* to Investors in Medical Building DST

Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.

Here's Why You Should Retain Fresenius Medical (FMS) for Now

Fresenius Medical's (FMS) shares decline more than 17% on Wednesday following news of the successful clinical trial of a competing drug in preventing kidney disease.

Fresenius Medical (FMS) Sinks on Potential Rise in Competition

Fresenius Medical Care (FMS) and Fresenius (FRE) stocks have experienced a decline due to the Novo Nordisk drug Ozempic ending a kidney failure study early. FMS remains a good player in the dialysis field and is not fundamentally impacted by the Ozempic report. FMS has the potential for significant improvement in the next few years, with a low-mid single-digit growth in revenues and a slight decline in EBIT forecasted for 2023.

Fresenius Medical Care: Don't Let The Ozempic Kidney Failure Scare You Off

Germany's Fresenius Medical Care , said that use of Ozempic, and other diabetes and weight-loss drugs of the same class, would have an overall neutral effect on how many patients will require the company's kidney dialysis services in the future.

Fresenius Medical: use of drugs like Ozempic has neutral effect on dialysis patient numbers

DaVita

Outset Medical

Novo Nordisk shares rallied after it announced it will stop its FLOW trial nearly a year earlier than expected after positive feedback on interim data for semaglutide's ability to treat kidney disease. The news sent dialysis products and services providers plunging.

Why Dialysis Stocks Plunged Today

Novo Nordisk ended a phase 3 trial early for Ozempic for preventing kidney disease because the trial was so successful. Fresenius and other dialysis-connected companies saw their shares fall on Wednesday.

Why Shares of Fresenius Medical Care Were Dropping on Wednesday

Baxter

Over $5bn in value was wiped from the three main operators in the dialysis market after a clinical trial update that offers hope for thousands of diabetes sufferers with kidney disease. Earlier, Novo Nordisk (NYSE:NVO) revealed that its Ozempic – a weekly jab which also doubles as a weight-loss aid – had proven successful in treating the new patient group mentioned above.

Novo Nordisk data knocks $5bn from the value of three leading dialysis companies

Markets were poised to move higher again on Wednesday morning. Shares of Novo Nordisk climbed on good news from a study of its drug Ozempic on kidney patients.

Ozempic Is Moving a Bunch of Stocks Wednesday Morning

KINSTON, N.C. , Oct. 11, 2023 /PRNewswire/ -- Capital Square, one of the nation's leading sponsors of tax-advantaged real estate investments and an active developer of multifamily communities, announced today the sale of a medical building in Kinston, North Carolina.

News for Fresenius Medical Care Stock (FMS)